Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies

In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al. 1 Lorusso D. Xiang Y. Hasegawa K. Scambia G. Leiva M. Ramos-Elias P. Acevedo A. Sukhin V. Cloven N. Pereira de Santana Gomes A.J. et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024; 403: 1341-1350https://doi.org/10.1016/S0140-6736(24)00317-9 Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival. In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al. 1 Lorusso D. Xiang Y. Hasegawa K. Scambia G. Leiva M. Ramos-Elias P. Acevedo A. Sukhin V. Cloven N. Pereira de Santana Gomes A.J. et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024; 403: 1341-1350https://doi.org/10.1016/S0140-6736(24)00317-9 Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.